Skip to main content

Advertisement

Table 2 Univariate and multivariate analysis for CKD progression and accelerated eGFR decline in patients with type 2 diabetes

From: Addition of nonalbumin proteinuria to albuminuria improves prediction of type 2 diabetic nephropathy progression

  Univariate analysis Multivariate analysisa
HR 95% CI P value HR 95% CI P value
CKD progression
 Model 1
  ACR < 30 1 Ref.   1 Ref.  
  ACR ≥ 30 4.22 1.76–10.11 0.001 3.43 1.34–8.76 0.010
 Model 2
  NAPCR < 120 1 Ref.   1 Ref.  
  NAPCR ≥ 120 7.59 2.60–22.15 <0.001 6.84 2.25–20.85 0.001
 Model 3
  ACR < 30; NAPCR < 120 1 Ref.   1 Ref.  
  ACR < 30; NAPCR ≥ 120 18.88 2.27–157.05 0.007 21.82 2.57–185.62 0.005
  ACR ≥ 30; NAPCR < 120 11.90 1.23–114.79 0.032 11.62 1.19–113.97 0.035
  ACR ≥ 30; NAPCR ≥ 120 27.27 3.60–206.66 0.001 21.40 2.70–169.78 0.004
Accelerated eGFR decline
 Model 1
  ACR < 30 1 Ref.   1 Ref.  
  ACR ≥ 30 1.72 1.08–02.76 0.024 1.55 0.92–2.61 0.100
 Model 2
  NAPCR < 120 1 Ref.   1 Ref.  
  NAPCR ≥ 120 2.01 1.25–3.24 0.004 1.95 1.16–3.26 0.011
 Model 3
  ACR < 30; NAPCR < 120 1 Ref.   1 Ref.  
  ACR < 30; NAPCR ≥ 120 1.64 0.81–3.31 0.170 1.66 0.81–3.43 0.169
  ACR ≥ 30; NAPCR < 120 1.21 0.52–2.84 0.659 1.12 0.47–2.70 0.800
  ACR ≥ 30; NAPCR ≥ 120 2.39 1.36–4.17 0.002 2.28 1.21–4.29 0.011
  1. Model 1, vs. normoalbuminuria; model 2, vs. NAPCR levels below 120 mg/g; model 3, vs. normoalbuminuria and NAPCR levels below 120 mg/g
  2. aAdjusted for age, sex, duration of diabetes, SBP, LDL, HbA1c, baseline eGFR, RAS inhibitor use and lipid-lowering agent use